Skip to content

Intrabio

IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling.

With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.

Patient and Trial Information

Taylor Fields, Senior Vice President
tfields@intrabio.com  |  intrabio.com 

Latest News

IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C. Click here for complete announcement.

10/19/2020

IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C. Click here for complete Announcement.

09/30/2020

IntraBio Receives Fast Track Designation from FDA for IB1001 Treatment of NPC. Click here for complete Announcement.

03/25/2020

IntraBio Announces Extension Phase for NPC Accepted in the United States. Click here for complete Announcement.

03/05/2020

IntraBio Completes NPC Clinical Trial Enrollment. Click here for complete announcement.

01/17/2020

IntraBio IB1001-201 Clinical Trial for NPC Reaches 2/3 of their Recruitment Goal. Click herefor complete announcement.

11/13/2019

IntraBio Clinical Trial IB1001-201 Open for US Recruitment at Mayo Clinic. Click here for complete announcement.

09/04/2019

IntraBio IB1001 Series Update

IntraBio is developing a number of small-molecule drug candidates that have broad applicability to rare and common neurological disorders, genetic, and inflammatory diseases. Their current lead drug candidate, IB1001, is initially being developed to treat three rare, genetic diseases where there are extremely high unmet medical needs: Niemann-Pick disease type C, GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and Ataxia-Telangiectasia (A-T; an inherited Cerebellar Ataxia). Click the link below for additional information.

Click here for IB1000 Series development history.

05/31/2019

NNPDF Industry Update Webinar Series featuring IntraBio, Inc. Click here for recording.

04/25/2019

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of NPC. Click here for complete announcement.

03/11/2019

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of NPC. Click here for complete announcement.

02/13/2019

IntraBio Receives Niemann-Pick disease Orphan Drug Designation from the FDA for IB1000 Series. Click here for complete announcement.

11/26/2018

Supporting one another. Supporting our community